One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).
These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.
Patients aged ≥18 years.
With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria.
Who have received at least one of the doses of the study drugs.
In follow-up in the consultations of the UGC of Rheumatology of the HUVM.
Patients where the medical records lack sufficient baseline and final variables to perform the analysis.
Patients in whom more than 50% of the variables to be collected are missing in the data collection.
Patients aged \> 18 years diagnosed with rheumatoid arthritis, who have been under treatment with at least one dose of the study drugs, whose treatment is followed by the rheumatology unit.
Case-only
Prospective
Not listed
7
Trial groupsSee each trial group below.
Survival study
To know the survival at 12, 24, 48, 60, 72 and 84 months to the synthetic directed anti-rheumatic drugs, disease modifiers (FAMEsd) and the biological disease modifying anti-rheumatic drugs (FAMEb) in patients with rheumatoid arthritis treated in routine.
Study of clinical characteristics.
To know the sociodemographic and clinical characteristics of the patients who receive FAMEsd and FAMEb in routine clinical practice at the HUVM.
Measure of the influence of comorbidities.
To assess the influence of comorbidities on drug persistence.
Number of participants who discontinued treatment due to serious adverse effects.
Failure due to serious adverse events, adverse events of special interest, emerging adverse events and minor adverse events that require discontinuation of the drug.
Click on the lead sponsor to view all of their trials.
